CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models

In spite of the efficacy of Her2-targeted therapies, recurrence and progression remain a challenge for treatment of Her2 positive breast cancer. CDK4/6 controls pathway downstream of Her2, Inhibition of these kinases could represent an important therapeutic approach to augment the effectiveness of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Witkiewicz, Agnieszka K., Cox, Derek, Knudsen, Erik S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162138/
https://www.ncbi.nlm.nih.gov/pubmed/25221644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162138/
https://www.ncbi.nlm.nih.gov/pubmed/25221644

Ejemplares similares